Valproate (Epilim) – Ongoing review of potential risk of NDD due to paternal exposure
15/09/2023
Medicines for human use
Direct healthcare professional communication (DHPC)
Valproate (Epilim▼) – ongoing review of potential risk of neurodevelopmental disorders in children of fathers treated with valproate in the three months prior to conception.